Search

Displaying results 9341 - 9350 of 10000 in total
  1. Drug

    Annamycin

    go.drugbank.com/drugs/DB06420
    Investigational

    Categories: P-glycoprotein inhibitors
  2. Drug

    TAK-751S

    go.drugbank.com/drugs/DB06432
    Investigational

    TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia coli_.[A260296]

    Synonyms: Synsorb Pk, Synsorb-Pk
  3. Drug

    Aprinocarsen

    go.drugbank.com/drugs/DB06451
    Investigational

    Aprinocarsen is a specific antisense oligonucleotide inhibitor of protein kinase C-alpha.

  4. Drug

    IR501

    go.drugbank.com/drugs/DB06464
    Experimental

    IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity.

  5. Drug

    Fradafiban

    go.drugbank.com/drugs/DB06472
    Experimental

  6. Drug

    Porfiromycin

    go.drugbank.com/drugs/DB06478
    Investigational

    Porfiromycin is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called anticancer antibiotics.

  7. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  8. Drug

    Resiniferatoxin

    go.drugbank.com/drugs/DB06515
    Investigational

    Resiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission

  9. Drug

    MLN576

    go.drugbank.com/drugs/DB06517
    Experimental

    XR11576 (MLN576) is a novel monophenazine with a mechanism of action that includes interaction with both topoisomerase (Topo) I and II.[A234609]

  10. Drug

    Iproniazid

    go.drugbank.com/drugs/DB04818
    ApprovedWithdrawn

    Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Cytochrome P-450 CYP2C9 Inhibitors